The Incretin Saga: Mimetics, Enhancers, and Inhibitors

Illustration of Incretin-based Therapies courtesy www.NDEI.org

| Apr 20, 2007

A lot of new medicines have come out, with a pile of new acronyms:  GLP-1, DPP-4, BYOB…well, that last one is probably familiar, but a little background on the other two might not be out of place. You’re going to be seeing a lot more of them in the future, and it’ll help to be on speaking terms.

First of all, what is an incretin, anyway?  An incretin is a hormone released from cells in the gut in response to eating food.  Incretins were discovered when scientists noticed that people secreted more insulin after actually eating glucose than after being given a comparable amount of glucose intravenously.  They knew there had to be a trigger for that extra insulin secretion, and the trigger was incretin.

Gulp-1, A Gutsy Incretin

The star incretin in diabetes treatment, and our hero in this little tale, is glucagon-like peptide-1, or GLP-1. After a meal, the gut secretes GLP-1 in response to the arrival of food from the stomach. GLP-1 then does several good things to lower blood sugar.  It binds to receptors on the pancreatic beta cells and stimulates the release of insulin. It also reduces the secretion of glucagon by the pancreas. (Glucagon causes the liver to convert glycogen to glucose, thereby increasing blood sugar.). In addition, GLP-1 slows down stomach emptying and nutrient absorption. In people without diabetes, this cycle works smoothly. In people with diabetes?  Not so much.

In diabetic people, our friendly incretin GLP-1 needs some help. Modern science has come up with two kinds of medicine that increase the action of GLP-1. The first are incretin enhancers, and the second are incretin mimetics.

Gulp Saved From Dip By the Gliptin Sisters

Without artificial help, our hero incretin GLP-1 is a bit of a weakling; it lasts only one or two minutes in the system.  That’s because an enzyme called DPP-4 (short for dipeptidyl peptidase 4) very efficiently breaks down GLP-1. In order to make GLP-1 last longer, a medicine is needed to slow down, or inhibit, the enzyme DPP-4.  In plain language, we need something to stop Dip the Destroyer from crunching our hero Gulp.

Vildagliptin  (Galvus by Novartis, not yet FDA approved) and sitagliptin (Januvia by Merck) are DPP-4 inhibitors.  By slowing the action of DPP-4, they delay the breakdown of GLP-1 and thereby enhance its action.  Now GLP-1 can stick around longer and carry out all the great blood glucose-lowering actions for which it is so justly famous.  It’s easy to remember these two medicines, our DPP-4 inhibitors, as the lovely sisters Vilda and Sita Gliptin, who whip the evil Dip.

Gulp Mime Lasts Longer

The second kind of incretin-increasing medicine is called an incretin mimetic.  It’s a medicine that outright copies, or mimics, the action of our hero incretin GLP-1, but is resistant to the evil enzyme DPP-4.  As a result, it can carry out its useful job for much longer than poor vulnerable GLP-1, who can’t stand up to DPP-4 for longer than a minute without breaking down.  Byetta (exenatide) is an incretin mimetic.  It is taken twice daily by injection.

So there you have the story, and now you’ll have a much easier time keeping all the characters straight.

Click Here To View Or Post Comments

Categories: Blood Glucose, Blood Sugar, Diabetes, Diabetes, Food, Insulin, Type 2 Medications


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (1)

You May Also Be Interested In...


Comments

Posted by MDLMD1 on 24 May 2009

Linda von Wartburg's article is very helpful to anyone who wants to keep the "mechanism of action" in mind when using the newer diabetes medications.

I suggest that the diabetes community adopt her memory aids when learning about incretin.

M. Lewis, M.D.


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.